Alumis Inc. - Common Stock (ALMS)

Nvidia, Apple, Microsoft, and select biotech names dominated early market buzz.

The company also disclosed plans of a $175 million underwritten share offering after releasing its Phase 3 trial data.

Investors today are cheering envudeucitinib's Phase 3 edge in oral TYK2 psoriasis as well as Alumis' plans to raise fresh capital.

The first week of 2026 has delivered a definitive verdict on the next phase of the bull market: the era of mega-cap dominance is yielding to the rise of the small-cap. In a dramatic "Great Rotation," investors are pulling capital from the expensive, AI-saturated titans of the Nasdaq and pouring

Alumis announced positive results from both of its Phase 3 clinical trials of envudeucitinib.

Markets seem to be balancing CES-driven AI optimism with caution ahead of upcoming jobs data.

A full exit during a volatile stretch raises a sharper question than timing alone.

Wondering how the US markets performed one hour before the close of the markets on Friday? Discover the movers and shakers of today's session in our comprehensive analysis.

Keep an eye on the top gainers and losers in Friday's session, as they reflect the most notable price movements.

Today's session on Tuesday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.

Curious to know what's happening on the US markets one hour before the close of the markets on Tuesday? Join us as we explore the top gainers and losers in today's session.

There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Tuesday.